Abstract
Background: Over the past few years, the benefits of
co-administration of omega-3 and antioxidants have been reported in the
management of non-alcoholic fatty liver disease (NAFLD)
complications.This study evaluated the effects of Camelina sativa oil
(CSO) supplementation as one of the richest dietary sources of omega-3
fatty acids on glucose homeostasis,inflammation, metabolic endotoxemia,
and oxidative stress in NAFLD patients.
Methods: In all, 43 subjects with NAFLD were allocated to
either an intervention (20g/d CSO) or placebo (20g/d sunflower oil)
group receiving a calorie-restricted diet for 12 weeks. Fasting serum
levels of glycemic indices, hs-CRP, endotoxin, antioxidant enzymes
activity, total antioxidant capacity (TAC), malondialdehyde (MDA),
8-iso-prostaglandin F2α (8-iso-PGF2α), and uric acid were measured at
baseline and post-intervention.
Results: CSO intake led to a significant decrease in insulin
concentration (-17.49%), homeostasis model assessment of insulin
resistance (HOMA-IR) (-20%), high-sensitive C-reactive protein
(hs-CRP), (-12.94%), lipopolysaccharide endotoxin (-32.55%),
malondialdehyde (MDA) (-18.75%), 8-iso-prostaglandin F2α (8-iso-PGF2α)
(-19.55%) and a significant increase in the levels of total antioxidant
capacity (TAC) (31.82%) and superoxide dismutase activity (10.22%) in
the CSO group compared with the placebo group. Also, there was no
significant difference between the two groups in fasting plasma glucose,
quantitative insulin sensitivity check index (QUICKI), catalase,
glutathione peroxidase activity, and uric acid level. In addition,
within-group analyses showed a significant reduction of insulin, QUICKI,
hs-CRP, and endotoxin levels in the intervention group.
Conclusion: These findings indicate that CSO may improve
glycemic, inflammation, metabolic endotoxima, oxidative stress status,
and mental health in patients with NAFLD.
Keywords: Camelina; glycemic; metabolic endotoxima, oxidative
stress, inflammation, NAFLD